Analysis of the core points of the instruction manual for Pyrotinib/Areni

Pyrotinib Maleate (Pyrotinib Maleate) is an oral small molecule irreversible tyrosine kinase inhibitor (TKI) independently developed in China. It mainly targets human epidermal growth factor receptor 2 (HER2) and also has inhibitory effects on HER1 (EGFR) and HER4. By blocking the HER2 signaling pathway, pyrotinib can effectively inhibit tumor cell proliferation and promote apoptosis, providing a precise targeted therapy for patients with HER2-positive breast cancer. Its property of irreversibly binding to HER2 makes it show significant advantages in recurrent or metastatic breast cancer and neoadjuvant treatment, providing a flexible and effective option for clinical treatment.

1. Drug information and indications

1. Recurrence/Metastatic breast cancer

Pyrotinib combined with capecitabine is suitable for patients with HER2-positive recurrent or metastatic breast cancer who have received or not received trastuzumab treatment in the past, but the patients must have received anthracycline or taxane chemotherapy. The combination program is designed to enhance anti-tumor effects and improve disease control rates.

Pyrotinib combined with trastuzumab and docetaxel is suitable for HER2-positive patients with recurrent or metastatic breast cancer who have not received anti-HER2 treatment in the advanced stage and provides an effective solution for initial anti-HER2 treatment.

2. Early or locally advanced breast cancer

Pyrotinib, combined with trastuzumab and docetaxel, is used for neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. It can effectively reduce the tumor volume before surgery and improve postoperative efficacy. The FEC regimen (5-fluorouracil, epirubicin, and cyclophosphamide) was continued for postoperative consolidation to prolong disease-free survival.

2. Usage and dosage

1. Oral single drug: The recommended dose of pyrotinib is 400 mg daily, taken orally at the same time every day, within 30 minutes after meals, and taken continuously, every 21 days as a cycle. If you miss a day, you do not need to make up for it and continue as planned.

2. Combined with capecitabine: The recommended dose of capecitabine is twice a day, the total dose2000mg/m², taken for 14 consecutive days and then rested for 7 days, with a cycle of 21 days. Take it with pyrotinib in the morning and within 30 minutes after a meal. Treatment was continued until disease progression or unacceptable toxicity occurred.

3. Combination of trastuzumab and docetaxel: The initial dose of trastuzumab is 8 mg/kg, followed by 6 mg/kg every 3 weeks; the starting dose of docetaxel is 75 mg/m² (relapsed or metastatic) or 100 mg/m² (early/locally advanced neoadjuvant treatment), administered every 3 weeks. Four cycles of neoadjuvant treatment are recommended, followed by 3 cycles of FEC regimen for consolidation after surgery.

3. Pharmacological mechanism and action advantages

Pyrotinib irreversibly inhibits the tyrosine kinase activities of HER2, HER1 and HER4, blocking the downstream PI3K/AKT and MAPK signaling pathways, thereby inhibiting tumor cell proliferation and inducing apoptosis.

It can provide effective tumor growth control for patients with HER2-positive breast cancer, especially those with recurrence/metastasis who have previously received trastuzumab or have not received anti-HER2 therapy.

Oral administration facilitates long-term management of patients. Compared with intravenous infusion therapy, it reduces the frequency of hospital visits and improves the quality of life.

Reference materials:https://www.drugs.com